Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials With Shernan Holtan, MD

At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, presented a late-breaking abstract on the BMT CTN 1703 trial of post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis after allogenic hematopoietic cell transplantation. Prior to the presentation, she sat down with Oncology Data Advisor to preview the trial's promising results and its potential to transform practice for GVHD.  

Continue reading

New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease With Shernan Holtan, MD, and Carrie Kitko, MD

Oncology Data Advisor™ · New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year...

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.